Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease

Neurobiology of Aging
Imelda S BarberKevin Morgan

Abstract

Early-onset Alzheimer's disease (EOAD) can be familial (FAD) or sporadic EOAD (sEOAD); both have a disease onset ≤65 years of age. A total of 451 sEOAD samples were screened for known causative mutations in exons 16 and 17 of the amyloid precursor protein (APP) gene. Four samples were shown to be heterozygous for 1 of 3 known causative mutations: p.A713T, p.V717I, and p.V717G; this highlights the importance of screening EOAD patients for causative mutations. Additionally, we document an intronic 6 base pair (bp) deletion located 83 bp downstream of exon 17 (rs367709245, IVS17 83-88delAAGTAT), which has a nonsignificantly increased minor allele frequency in our sEOAD cohort (0.006) compared to LOAD (0.002) and controls (0.002). To assess the effect of the 6-bp deletion on splicing, COS-7 and BE(2)-C cells were transfected with a minigene vector encompassing exon 17. There was no change in splicing of exon 17 from constructs containing either wild type or deletion inserts. Sequencing of cDNA generated from cerebellum and temporal cortex of a patient harboring the deletion found no evidence of transcripts with exon 17 removed.

References

Aug 18, 1995·Science·E Levy-LahadG D Schellenberg
Nov 16, 2002·Archives of Neurology·Ron BrookmeyerClaudia Kawas
Jun 17, 2004·Journal of Neurochemistry·Qingming YuJianhua Zhou
Jul 12, 2008·Molecular Neurodegeneration·Fei Liu, Cheng-Xin Gong
Apr 3, 2009·Nucleic Acids Research·François-Olivier DesmetChristophe Béroud
May 15, 2012·Human Mutation·Marc CrutsChristine Van Broeckhoven
Jun 15, 2014·Neurology·Davis C RymanUNKNOWN Dominantly Inherited Alzheimer Network
Dec 3, 2014·Neurobiology of Aging·Mike A NallsUNKNOWN Parkinson's Disease meta-analysis consortium

❮ Previous
Next ❯

Citations

Feb 2, 2019·Continuum : Lifelong Learning in Neurology·Mario F Mendez
Mar 30, 2017·PLoS Medicine·Hélène-Marie LanoiseléeUNKNOWN collaborators of the CNR-MAJ project

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.